Revenues surge at cystic fibrosis drug firm

Pharmaceutical firm Vertex Ireland’s revenues soared last year on the back of the company's deal with the HSE on the groundbreaking blockbuster cystic fibrosis drug Orkambi.

Newly-filed accounts for the company show its revenues surged 71% to €60m. In June 2017, Vertex Ireland reached an agreement with the HSE for the sale of Orkambi to around 600 people with cystic fibrosis in Ireland.